Viviani V, Fantoni A, Tomei S, Marchi S, Luzzi E, Bodini M
NPJ Vaccines. 2023; 8(1):54.
PMID: 37045859
PMC: 10097807.
DOI: 10.1038/s41541-023-00651-9.
Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani M, Panatto D
J Immunol Res. 2015; 2015:353461.
PMID: 26351645
PMC: 4553328.
DOI: 10.1155/2015/353461.
Alamro M, Bidmos F, Chan H, Oldfield N, Newton E, Bai X
Infect Immun. 2014; 82(6):2472-84.
PMID: 24686058
PMC: 4019173.
DOI: 10.1128/IAI.01521-14.
Panatto D, Amicizia D, Lai P, Cristina M, Domnich A, Gasparini R
Indian J Med Res. 2014; 138(6):835-46.
PMID: 24521624
PMC: 3978970.
Williams J, Skipp P, OConnor C, Christodoulides M, Heckels J
Infect Immun. 2009; 77(11):5080-9.
PMID: 19737898
PMC: 2772525.
DOI: 10.1128/IAI.00701-09.
Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.
Norheim G, Aseffa A, Yassin M, Mengistu G, Kassu A, Fikremariam D
Clin Vaccine Immunol. 2008; 15(5):863-71.
PMID: 18337382
PMC: 2394845.
DOI: 10.1128/CVI.00252-07.
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
Wedege E, Bolstad K, Aase A, Herstad T, McCallum L, Rosenqvist E
Clin Vaccine Immunol. 2007; 14(7):830-8.
PMID: 17494638
PMC: 1951067.
DOI: 10.1128/CVI.00039-07.
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.
Borrow R, Aaberge I, Santos G, Eudey T, Oster P, Glennie A
Clin Diagn Lab Immunol. 2005; 12(8):970-6.
PMID: 16085915
PMC: 1182195.
DOI: 10.1128/CDLI.12.8.970-976.2005.
Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
Welsch J, Granoff D
Infect Immun. 2004; 72(10):5903-9.
PMID: 15385492
PMC: 517551.
DOI: 10.1128/IAI.72.10.5903-5909.2004.
Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
Wedege E, Kuipers B, Bolstad K, van Dijken H, Froholm L, Vermont C
Infect Immun. 2003; 71(7):3775-81.
PMID: 12819059
PMC: 162037.
DOI: 10.1128/IAI.71.7.3775-3781.2003.
Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
Vermont C, Van Dijken H, Kuipers A, van Limpt C, Keijzers W, van der Ende A
Infect Immun. 2003; 71(4):1650-5.
PMID: 12654777
PMC: 152051.
DOI: 10.1128/IAI.71.4.1650-1655.2003.
Carcinoembryonic antigen family receptor recognition by gonococcal Opa proteins requires distinct combinations of hypervariable Opa protein domains.
Bos M, Kao D, Hogan D, Grant C, Belland R
Infect Immun. 2002; 70(4):1715-23.
PMID: 11895933
PMC: 127850.
DOI: 10.1128/IAI.70.4.1715-1723.2002.
Characterization of humoral and cellular immune responses elicited by meningococcal carriage.
Robinson K, Neal K, Howard C, Stockton J, Atkinson K, Scarth E
Infect Immun. 2002; 70(3):1301-9.
PMID: 11854214
PMC: 127751.
DOI: 10.1128/IAI.70.3.1301-1309.2002.
Differences in surface expression of NspA among Neisseria meningitidis group B strains.
Moe G, Tan S, Granoff D
Infect Immun. 1999; 67(11):5664-75.
PMID: 10531214
PMC: 96940.
DOI: 10.1128/IAI.67.11.5664-5675.1999.
Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.
Milagres L, Gorla M, Sacchi C, Rodrigues M
Infect Immun. 1998; 66(10):4755-61.
PMID: 9746575
PMC: 108586.
DOI: 10.1128/IAI.66.10.4755-4761.1998.
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
Wedege E, Hoiby E, Rosenqvist E, Bjune G
Infect Immun. 1998; 66(7):3223-31.
PMID: 9632589
PMC: 108336.
DOI: 10.1128/IAI.66.7.3223-3231.1998.
Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.
Haneberg B, Dalseg R, Wedege E, Hoiby E, Haugen I, Oftung F
Infect Immun. 1998; 66(4):1334-41.
PMID: 9529050
PMC: 108057.
DOI: 10.1128/IAI.66.4.1334-1341.1998.
Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.
Martin D, Cadieux N, Hamel J, Brodeur B
J Exp Med. 1997; 185(7):1173-83.
PMID: 9104804
PMC: 2196255.
DOI: 10.1084/jem.185.7.1173.
T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins.
Wiertz E, Delvig A, Donders E, Brugghe H, van Unen L, Timmermans H
Infect Immun. 1996; 64(1):298-304.
PMID: 8557355
PMC: 173759.
DOI: 10.1128/iai.64.1.298-304.1996.
Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population.
Caugant D, Hoiby E, Magnus P, Scheel O, Hoel T, Bjune G
J Clin Microbiol. 1994; 32(2):323-30.
PMID: 8150942
PMC: 263032.
DOI: 10.1128/jcm.32.2.323-330.1994.